FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313304060> ?p ?o ?g. }

• W4313304060 abstract "Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive triple negative breast cancer (TNBC). Atezolizumab with anthracycline- and taxane-based neoadjuvant chemotherapy has also shown increased pathological complete response (pCR) rates in early TNBC. This trial evaluated neoadjuvant carboplatin and paclitaxel with or without atezolizumab in patients with clinical stages II-III TNBC. The co-primary objectives were to evaluate if chemotherapy and atezolizumab increase pCR rate and tumor infiltrating lymphocyte (TIL) percentage compared to chemotherapy alone in the mITT population. Sixty-seven patients (ages 25-78 years; median, 52 years) were randomly assigned - 22 patients to Arm A, and 45 to Arm B. Median follow up was 6.6 months. In the modified intent to treat population (all patients evaluable for the primary endpoints who received at least one dose of combination therapy), the pCR rate was 18.8% (95% CI 4.0-45.6%) in Arm A, and 55.6% (95% CI 40.0-70.4%) in Arm B (estimated treatment difference: 36.8%, 95% CI 8.5-56.6%; p = 0.018). Grade 3 or higher treatment-related adverse events occurred in 62.5% of patients in Arm A, and 57.8% of patients in Arm B. One patient in Arm B died from recurrent disease during the follow-up period. TIL percentage increased slightly from baseline to cycle 1 in both Arm A (mean ± SD: 0.6% ± 21.0%) and Arm B (5.7% ± 15.8%) (p = 0.36). Patients with pCR had higher median TIL percentages (24.8%) than those with non-pCR (14.2%) (p = 0.02). Although subgroup analyses were limited by the small sample size, PD-L1-positive patients treated with chemotherapy and atezolizumab had a pCR rate of 75% (12/16). The addition of atezolizumab to neoadjuvant carboplatin and paclitaxel resulted in a statistically significant and clinically relevant increased pCR rate in patients with clinical stages II and III TNBC. (Funded by National Cancer Institute)." @default.
• W4313304060 created "2023-01-06" @default.
• W4313304060 creator A5004313839 @default.
• W4313304060 creator A5004542056 @default.
• W4313304060 creator A5008654358 @default.
• W4313304060 creator A5016973435 @default.
• W4313304060 creator A5019874570 @default.
• W4313304060 creator A5022594161 @default.
• W4313304060 creator A5027821205 @default.
• W4313304060 creator A5030653735 @default.
• W4313304060 creator A5036750199 @default.
• W4313304060 creator A5037350457 @default.
• W4313304060 creator A5040097257 @default.
• W4313304060 creator A5041161932 @default.
• W4313304060 creator A5044108002 @default.
• W4313304060 creator A5044382803 @default.
• W4313304060 creator A5048646563 @default.
• W4313304060 creator A5051448925 @default.
• W4313304060 creator A5057265018 @default.
• W4313304060 creator A5058975989 @default.
• W4313304060 creator A5059723987 @default.
• W4313304060 creator A5061892063 @default.
• W4313304060 creator A5064321807 @default.
• W4313304060 creator A5065771969 @default.
• W4313304060 creator A5066128896 @default.
• W4313304060 creator A5071788399 @default.
• W4313304060 creator A5075280020 @default.
• W4313304060 creator A5077763512 @default.
• W4313304060 date "2022-12-30" @default.
• W4313304060 modified "2023-10-04" @default.
• W4313304060 title "A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013" @default.
• W4313304060 cites W1489445081 @default.
• W4313304060 cites W1701849548 @default.
• W4313304060 cites W1873896754 @default.
• W4313304060 cites W1929478668 @default.
• W4313304060 cites W1965367061 @default.
• W4313304060 cites W1975401903 @default.
• W4313304060 cites W1985459298 @default.
• W4313304060 cites W1994238092 @default.
• W4313304060 cites W1996145004 @default.
• W4313304060 cites W2018968534 @default.
• W4313304060 cites W2022495797 @default.
• W4313304060 cites W2029086221 @default.
• W4313304060 cites W2050302729 @default.
• W4313304060 cites W2057186227 @default.
• W4313304060 cites W2063382533 @default.
• W4313304060 cites W2086064725 @default.
• W4313304060 cites W2096745115 @default.
• W4313304060 cites W2098683355 @default.
• W4313304060 cites W2100413206 @default.
• W4313304060 cites W2108855090 @default.
• W4313304060 cites W2118605519 @default.
• W4313304060 cites W2120431466 @default.
• W4313304060 cites W2121626779 @default.
• W4313304060 cites W2122639773 @default.
• W4313304060 cites W2124427232 @default.
• W4313304060 cites W2125885282 @default.
• W4313304060 cites W2134878729 @default.
• W4313304060 cites W2135800076 @default.
• W4313304060 cites W2136313650 @default.
• W4313304060 cites W2147415463 @default.
• W4313304060 cites W2155464214 @default.
• W4313304060 cites W2158742893 @default.
• W4313304060 cites W2170602872 @default.
• W4313304060 cites W2277555391 @default.
• W4313304060 cites W2434209561 @default.
• W4313304060 cites W2466558384 @default.
• W4313304060 cites W2559804019 @default.
• W4313304060 cites W2577007969 @default.
• W4313304060 cites W2762554941 @default.
• W4313304060 cites W2796582438 @default.
• W4313304060 cites W2805354595 @default.
• W4313304060 cites W2806209829 @default.
• W4313304060 cites W2886991068 @default.
• W4313304060 cites W2893960509 @default.
• W4313304060 cites W2897422388 @default.
• W4313304060 cites W2946386783 @default.
• W4313304060 cites W2979291688 @default.
• W4313304060 cites W2990398119 @default.
• W4313304060 cites W3006930853 @default.
• W4313304060 cites W3008792561 @default.
• W4313304060 cites W3009233496 @default.
• W4313304060 cites W3025022288 @default.
• W4313304060 cites W3087393791 @default.
• W4313304060 cites W3087992877 @default.
• W4313304060 cites W3160460588 @default.
• W4313304060 cites W4213010786 @default.
• W4313304060 doi "https://doi.org/10.1038/s41523-022-00500-3" @default.
• W4313304060 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36585404" @default.
• W4313304060 hasPublicationYear "2022" @default.
• W4313304060 type Work @default.
• W4313304060 citedByCount "5" @default.
• W4313304060 countsByYear W43133040602022 @default.
• W4313304060 countsByYear W43133040602023 @default.
• W4313304060 crossrefType "journal-article" @default.
• W4313304060 hasAuthorship W4313304060A5004313839 @default.
• W4313304060 hasAuthorship W4313304060A5004542056 @default.
• W4313304060 hasAuthorship W4313304060A5008654358 @default.
• W4313304060 hasAuthorship W4313304060A5016973435 @default.
• W4313304060 hasAuthorship W4313304060A5019874570 @default.

• next